AbbVievsProtalix BioTherapeutics

ABBV and PLX stock compared: price, dividend, valuation and results, from SEC filings.

PLX

Protalix BioTherapeutics, Inc.

$3.01

Value $243M

-1.31%
PLX's page

AbbVie (ABBV) has a market value of $527B and Protalix BioTherapeutics (PLX) $243M. Over the last year, with dividends, ABBV moved +32.0% and PLX +61.8%. The P/E is 51.2 for ABBV and 11.8 for PLX. Dividend yield: ABBV 2.32%, PLX none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$527B

    PLX$243M

    ABBV is 2,172 times PLX

  • Revenue, 12 months

    ABBV$66.0B

    PLX$85M

    ABBV is 779 times PLX

  • Net income, 12 months

    ABBV$10.3B

    PLX$21M

    ABBV is 503 times PLX

  • Operating margin

    ABBV32.2%

    PLX29.8%

    2.4 points apart

  • ROIC

    ABBV25.7%

    PLX31.3%

    5.6 points apart

  • P/E

    ABBV51.2

    PLX11.8

    ABBV is 4.3 times PLX

  • Dividend yield

    ABBV2.3%

    PLX0.0%

    2.3 points apart

  • 5-year return

    ABBV+204.7%

    PLX+161.7%

    43.0 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABBV+204.7%

PLX+161.7%

10020030020222023202420252026
Returns by period
PeriodABBVWith dividendsPLXWith dividends
1 year since November 14, 2025+32.0%Price +28.2%+61.8%Price +61.8%
3 years since November 16, 2023+138.1%+33.5% a yearPrice +115.4%+116.5%+29.4% a yearPrice +116.5%
5 years since November 15, 2021+204.7%+25.0% a yearPrice +154.9%+161.7%+21.2% a yearPrice +161.7%
10 years since November 16, 2016+627.5%+22.0% a yearPrice +383.9%-42.1%-5.3% a yearPrice -42.1%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbViePLXProtalix BioTherapeutics

Valuation

ABBVPLX
Valuation
Price$297.91$3.01
Market value$527B$243M
Enterprise value (EV)$597B$220M
P/E51.211.8
P/E, 5-year median57.0–
P/B–3.0
EV/EBIT28.18.8
Free cash flow yield3.6%6.2%

Results and growth

ABBVPLX
Results and growth
Revenue, 12 months$66.0B$85M
Net income, 12 months$10.3B$21M
Free cash flow, 12 months$18.9B$15M
Earnings per share, 12 months$5.81$0.25
Revenue growth, year on year8.6%-1.2%
Revenue growth a year, past+5.9%over 5 years-3.5%over 5 years
EPS growth a year, past-2.8%over 5 years–

Margins and returns on capital

ABBVPLX
Margins and returns on capital
Gross margin73.7%71.2%
Operating margin32.2%29.8%
Net margin15.7%24.3%
ROIC25.7%31.3%
ROE–32.1%

Balance sheet

ABBVPLX
Balance sheet
Cash$10.8B$22M
Total debt$80.9B$9.1M
Net debt / EBITDA3.2-0.8
Interest cover7.1×–

Dividends and buybacks

ABBVPLX
Dividends and buybacks
Dividend yield2.3%–
Dividend per share, 12 months$6.92–
Dividend growth a year, past+6.6%over 5 years–
Buyback yield0.2%–
Shareholder yield2.5%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or PLX

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or Protalix BioTherapeutics?

By market value, AbbVie ($527B) is about 2,172.0 times Protalix BioTherapeutics ($243M), at today's prices.

How did ABBV and PLX stock do over the last 10 years?

Since November 16, 2016, ABBV's price moved +383.9% and PLX's -42.1%. With dividends: ABBV +627.5% (+22.0% a year), PLX -42.1% (-5.3% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABBV or PLX?

The dividend yield at today's price is 2.32% for AbbVie and none for Protalix BioTherapeutics. Over the last twelve months they paid $6.92 and – per share.

What is the P/E of ABBV and PLX?

At today's price, the P/E is 51.2 for ABBV and 11.8 for PLX. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, AbbVie or Protalix BioTherapeutics?

Over the last twelve months, the net margin was 15.7% for AbbVie and 24.3% for Protalix BioTherapeutics, and the operating margin 32.2% and 29.8%. Revenue was $66.0B and $85M.

Which is the better investment, AbbVie or Protalix BioTherapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.